Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

4 recruiting

Enrollment Performance

Analytics

Phase 1
3(75.0%)
N/A
1(25.0%)
4Total
Phase 1(3)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT06760364Phase 1Recruiting

A Clinical Study of CHT102 in MSLN-Positive Advanced Pancreatic Cancer

Role: collaborator

NCT06914037Phase 1Recruiting

A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological Malignancies

Role: collaborator

NCT06730659Phase 1Recruiting

A Clinical Study of CHT101 in CD70-Positive Advanced Solid Tumors

Role: collaborator

NCT06717022Not ApplicableRecruiting

A Clinical Study of CHT102 in Mesothelin Positive Advanced Solid Tumors

Role: collaborator

All 4 trials loaded